Ingevity Corp(NGVT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,329 of 2,879 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
NGVT Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Ingevity Corp (NGVT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NGVT at 52.7/100 on a 32-signal composite quality model, placing it at rank #1,329 of 2,879 stocks — the top half of the AI-ranked universe. NGVT scores in the top quartile across revenue growth (87.2). Areas of concern include institutional flow (26.1) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 45.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Ingevity Corp reports quarterly revenue of $258.0M, net income of $59.8M, free cash flow of $-12.3M. Top institutional holders of NGVT by reported 13-F value include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. NGVT trades on the NYSE exchange and files with the SEC under CIK 1653477. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NGVT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ingevity Corp directly from SEC EDGAR. Ingevity Corp's 13F Pro composite quality score has ranged between 8 and 66 since 2021, currently 52.7 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.
Revenue
Q1 2026
$258.0M
Net Income
Q1 2026
$59.8M
Free Cash Flow
Q1 2026
$-12.3M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-2.7% YoYNet Income
+61.2% YoYOperating Income
-1.7% YoYEPS (Diluted)
+61.1% YoYTotal Assets
-18.4% YoYTotal Debt
-13.7% YoYOp. Cash Flow
+157.5% YoY| Metric | FY 2025 | FY 2024 | FY 2022 | FY 2019 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $1.17B -2.7% | $1.20B -28.1% | $1.67B +29.0% | $1.29B +33.0% | $972.4M +7.1% | $908.3M |
| Net Income | $-167.1M +61.2% | $-430.3M -303.4% | $211.6M +15.2% | $183.7M +45.2% | $126.5M +259.4% | $35.2M |
| Operating Income | $418.7M -1.7% | $425.9M -5.9% | $452.6M +14.0% | $396.9M +63.5% | $242.7M +48.3% | $163.6M |
| EPS (Diluted) | $-4.61 +61.1% | $-11.85 -315.5% | $5.50 +26.4% | $4.35 +46.5% | $2.97 +257.8% | $0.83 |
| Total Assets | $1.65B -18.4% | $2.02B -26.1% | $2.74B +27.8% | $2.14B +130.4% | $929.6M +11.6% | $832.8M |
| Total Debt | $1.21B -13.7% | $1.40B -4.9% | $1.47B +17.1% | $1.26B +176.4% | $455.0M -7.5% | $491.9M |
| Operating Cash Flow | $331.2M +157.5% | $128.6M -59.0% | $313.4M +13.7% | $275.7M +58.2% | $174.3M +36.3% | $127.9M |
AI Insight: NGVT Financial Trends
Revenue declined 9% year-over-year in Q1 2026 while debt reduction continued with total debt falling from $1,504M to $1,204M over eight quarters.
• Total debt decreased steadily from $1,504M in Q2 2024 to $1,204M in Q1 2026, a $300M reduction.
• Operating cash flow turned negative to -$2M in Q1 2026 after reaching $130M in Q3 2025.
• Equity declined from $285M in Q2 2024 to $39M in Q1 2026, an 86% decrease.
⚠ Net income volatility continues with swings from $60M profit in Q1 2026 to -$85M loss in Q4 2025.
⚠ Operating income data missing for recent four quarters limits visibility into operational performance trends.
AI Insight: NGVT Ratio Trends
Ingevity's profitability has turned volatile with operating margin swinging from -41.3% in Q4 2025 to 11.7% in Q1 2026.
• Operating margin deteriorated from 53.5% in Q3 2024 to -12.2% TTM through Q1 2026.
• Net profit margin improved from -33.2% in Q4 2025 to 23.2% in Q1 2026.
• ROIC turned negative at -11.2% TTM after reaching 34.5% in Q4 2024.
• Debt-to-equity ratio surged from 5.28 in Q2 2024 to 30.96 in Q1 2026.
⚠ Extreme quarterly margin volatility suggests operational instability or one-off impacts affecting core business performance.
⚠ Leverage increase of over 5x in two years raises financial risk concerns.
Get alerted when NGVT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Ingevity Corp including:
Top Institutional Holders of NGVT
BlackRock, Inc.
$377.4M5,297,715 shVANGUARD PORTFOLIO MANAGEMENT LLC
$155.0M2,176,731 shVANGUARD CAPITAL MANAGEMENT LLC
$112.7M1,581,871 shWELLINGTON MANAGEMENT GROUP LLP
$106.4M1,494,292 shSTATE STREET CORP
$103.9M1,459,235 shAMERICAN CENTURY COMPANIES INC
$102.0M1,432,566 shMILLENNIUM MANAGEMENT LLC
$82.3M1,155,372 shSEGALL BRYANT & HAMILL, LLC
$72.3M1,127,377 shBROWN ADVISORY INC
$70.7M992,016 shSimcoe Capital Management, LLC
$69.9M982,015 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $377.4M | 5,297,715 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $155.0M | 2,176,731 |
| VANGUARD CAPITAL MANAGEMENT LLC | $112.7M | 1,581,871 |
| WELLINGTON MANAGEMENT GROUP LLP | $106.4M | 1,494,292 |
| STATE STREET CORP | $103.9M | 1,459,235 |
| AMERICAN CENTURY COMPANIES INC | $102.0M | 1,432,566 |
| MILLENNIUM MANAGEMENT LLC | $82.3M | 1,155,372 |
| SEGALL BRYANT & HAMILL, LLC | $72.3M | 1,127,377 |
| BROWN ADVISORY INC | $70.7M | 992,016 |
| Simcoe Capital Management, LLC | $69.9M | 982,015 |
More Healthcare Companies
View all Healthcare →Put NGVT on your watchlist
Track score changes the day Ingevity Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NGVT a good stock to buy?
13F Pro's AI-powered analysis of Ingevity Corp (NGVT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NGVT are available on the NGVT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own NGVT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NGVT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Ingevity Corp's investment landscape.